Hong-Mei Zhang (Hongmei Zhang)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 16

Top Topics

Combination Therapy

Liver Metastases

Tyrosine Kinase

Top Venues

Journal of clinical medicine

Pharmaceuticals (Basel, Switzerland)

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Zuo-Yao Long, Yajie Lu, Minghui Li, Zhanli Fu, Yunus Akbar, Jing Li, Guojing Chen, Hong-Mei Zhang, Qi Wang, Liangbi Xiang, Zhen Wang
Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. Cancers 15 (3) (2023)
Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC? Journal of clinical medicine 12 (4) (2023)
Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC? Journal of clinical medicine 12 (4) (2023)
Yajie Lu, Wei Pan, Shizhou Deng, Qiongyi Dou, Xiangxu Wang, Qiang An, Xiaowen Wang, Hongchen Ji, Yue Hei, Yan Chen, Jingyue Yang, Hong-Mei Zhang
Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Yajie Lu, Wei Pan, Shizhou Deng, Qiongyi Dou, Xiangxu Wang, Qiang An, Xiaowen Wang, Hongchen Ji, Yue Hei, Yan Chen, Jingyue Yang, Hong-Mei Zhang
Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC? Journal of clinical medicine 12 (4) (2023)
Yajie Lu, Wei Pan, Shizhou Deng, Qiongyi Dou, Xiangxu Wang, Qiang An, Xiaowen Wang, Hongchen Ji, Yue Hei, Yan Chen, Jingyue Yang, Hong-Mei Zhang
Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC? Journal of clinical medicine 12 (4) (2023)
Yajie Lu, Wei Pan, Shizhou Deng, Qiongyi Dou, Xiangxu Wang, Qiang An, Xiaowen Wang, Hongchen Ji, Yue Hei, Yan Chen, Jingyue Yang, Hong-Mei Zhang
Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Zuo-Yao Long, Yajie Lu, Minghui Li, Zhanli Fu, Yunus Akbar, Jing Li, Guojing Chen, Hong-Mei Zhang, Qi Wang, Liangbi Xiang, Zhen Wang
Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. Cancers 15 (3) (2023)
Yize Li, Yinmiao Bai, Hongchen Ji, Zhihui Liu, Hong-Mei Zhang
New era: prospects for managing cancer of unknown primary. Cancer biology & medicine (2023)
Shu-Kui Qin, Jin Li, Yuxian Bai, Zishu Wang, Zhendong Chen, Rui-Hua Xu, Jian-Ming Xu, Hong-Mei Zhang, Jia Chen, Ying Yuan, Tianshu Liu, Lin Yang, Haijun Zhong, Donghui Chen, Lin Shen, Chunyi Hao, Deliang Fu, Ying Cheng, Jianwei Yang, Qiong Wang, Baoli Qin, Hongming Pan, Jun Zhang, Xianhong Bai, Qingshan Zheng
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Rui-Xia Yang, Yue Hei, Wen-Ting Zhu, Qian-Rong Wang, Hong-Mei Zhang, Yan Chen
Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report. Current oncology (Toronto, Ont.) 29 (9) (2022)
Yue Hei, Ruixia Yang, Shengnan Kong, Hong-Mei Zhang, Yan Chen
Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report. Journal of clinical medicine 12 (1) (2022)
Yue Hei, Ruixia Yang, Shengnan Kong, Hong-Mei Zhang, Yan Chen
Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report. Journal of clinical medicine 12 (1) (2022)
Yue Hei, Ruixia Yang, Shengnan Kong, Hong-Mei Zhang, Yan Chen
Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report. Journal of clinical medicine 12 (1) (2022)